



As Executive Director, Global Value Access and Policy for Amgen's Biosimilars Business Unit, Chad Pettit develops global market access launch strategy for Amgen's portfolio of 10 biosimilar medicines. He serves as a liaison with the biopharmaceutical industry on policy matters in biosimilars, a rapidly growing segment of the Amgen business. With his global perspective, Chad is recognized as an expert on biosimilar commercialization, market access for biosimilars, and the policy measures required to facilitate cost savings for patients and the health care system over the long-run.

Chad's 20 years of experience at Amgen have included service as the Amgen board member of the US Biosimilars Forum industry trade group, and a career focus on pricing, market access, and policy crossing all global regions in a broad range of roles in the US and Europe.

Chad received his MBA from the University of California Los Angeles, Anderson School of Management, and holds a B.S. in Chemical Engineering from the University of California Davis. In his spare time, he provides leadership and service within the community, enjoys the outdoors, and spends time with his wife Amy and four children.

Areas of expertise include:

- Global health economics policy and advocacy;
- Global payer and market access;
- Global value messaging and value-based partnerships;
- International and regional value, access and pricing;
- Biologic and biosimilar policy; and
- Public speaking